Your browser doesn't support javascript.
loading
Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
Böttcher, Jark; Dilworth, David; Reiser, Ulrich; Neumüller, Ralph A; Schleicher, Michael; Petronczki, Mark; Zeeb, Markus; Mischerikow, Nikolai; Allali-Hassani, Abdellah; Szewczyk, Magdalena M; Li, Fengling; Kennedy, Steven; Vedadi, Masoud; Barsyte-Lovejoy, Dalia; Brown, Peter J; Huber, Kilian V M; Rogers, Catherine M; Wells, Carrow I; Fedorov, Oleg; Rumpel, Klaus; Zoephel, Andreas; Mayer, Moriz; Wunberg, Tobias; Böse, Dietrich; Zahn, Stephan; Arnhof, Heribert; Berger, Helmut; Reiser, Christoph; Hörmann, Alexandra; Krammer, Teresa; Corcokovic, Maja; Sharps, Bernadette; Winkler, Sandra; Häring, Daniela; Cockcroft, Xiao-Ling; Fuchs, Julian E; Müllauer, Barbara; Weiss-Puxbaum, Alexander; Gerstberger, Thomas; Boehmelt, Guido; Vakoc, Christopher R; Arrowsmith, Cheryl H; Pearson, Mark; McConnell, Darryl B.
Afiliação
  • Böttcher J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. jark.boettcher@boehringer-ingelheim.com.
  • Dilworth D; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Reiser U; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Neumüller RA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Schleicher M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Petronczki M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Zeeb M; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
  • Mischerikow N; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Allali-Hassani A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Szewczyk MM; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Kennedy S; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Vedadi M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Barsyte-Lovejoy D; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Brown PJ; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Huber KVM; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Rogers CM; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wells CI; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Fedorov O; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Rumpel K; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Zoephel A; Structural Genomics Consortium, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Mayer M; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wunberg T; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Böse D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Zahn S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Arnhof H; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Berger H; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Reiser C; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Hörmann A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Krammer T; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Corcokovic M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Sharps B; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Winkler S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Häring D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Cockcroft XL; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Fuchs JE; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Müllauer B; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Weiss-Puxbaum A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Gerstberger T; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Boehmelt G; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Vakoc CR; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Arrowsmith CH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Pearson M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • McConnell DB; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Nat Chem Biol ; 15(8): 822-829, 2019 08.
Article em En | MEDLINE | ID: mdl-31285596
ABSTRACT
Here, we report the fragment-based discovery of BI-9321, a potent, selective and cellular active antagonist of the NSD3-PWWP1 domain. The human NSD3 protein is encoded by the WHSC1L1 gene located in the 8p11-p12 amplicon, frequently amplified in breast and squamous lung cancer. Recently, it was demonstrated that the PWWP1 domain of NSD3 is required for the viability of acute myeloid leukemia cells. To further elucidate the relevance of NSD3 in cancer biology, we developed a chemical probe, BI-9321, targeting the methyl-lysine binding site of the PWWP1 domain with sub-micromolar in vitro activity and cellular target engagement at 1 µM. As a single agent, BI-9321 downregulates Myc messenger RNA expression and reduces proliferation in MOLM-13 cells. This first-in-class chemical probe BI-9321, together with the negative control BI-9466, will greatly facilitate the elucidation of the underexplored biological function of PWWP domains.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Histona-Lisina N-Metiltransferase Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Histona-Lisina N-Metiltransferase Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article